Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
Summary
Phanes Therapeutics announced updated Phase 2 results for spevatamig in frontline metastatic pancreatic ductal adenocarcinoma. The company said the antibody combined with chemotherapy showed promising efficacy and tolerability in the first dose level. Phanes indicated that enrollment continues at the higher dose level and that it could be Phase 3 ready soon after more efficacy data arrive in the second half of 2026. The update supports continued development of the program and a future randomized registrational study.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected